D. Western Therapeutics Institute (TSE:4576) Preferred Stock: 円0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4576 D. Western Therapeutics Institute Inc TSE:4576
47 GF Score
Price 円75.00
GF Value 円68.18
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is D. Western Therapeutics Institute Preferred Stock?

D. Western Therapeutics Institute TSE:4576 47 Preferred Stock is 円0.00 Mil as of Dec. 2025. GuruFocus rates TSE:4576 with a GF Score™ of 47/100 and a GF Value™ of 円68.18 (Fairly Valued). The stock has 3 warning signs investors should review.

Preferred stock is a special equity security that has properties of both equity and debt. D. Western Therapeutics Institute's preferred stock for the quarter that ended in Dec. 2025 was 円0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. D. Western Therapeutics Institute's Enterprise Value for the quarter that ended in Dec. 2025 was 円4,103.48 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. D. Western Therapeutics Institute's Book Value per Share for the quarter that ended in Dec. 2025 was 円26.46.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). D. Western Therapeutics Institute's Earnings per Share (Diluted) for the three months ended in Dec. 2025 was 円0.00.


D. Western Therapeutics Institute  (TSE:4576) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

D. Western Therapeutics Institute's Enterprise Value for the quarter that ended in Dec. 2025 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

D. Western Therapeutics Institute's Book Value per Share for the quarter that ended in Dec. 2025 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

D. Western Therapeutics Institute's Earnings per Share (Diluted) (EPS) for the three months ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


D. Western Therapeutics Institute Preferred Stock Related Terms


D. Western Therapeutics Institute Preferred Stock Historical Data

* Premium members only.

The historical data trend for D. Western Therapeutics Institute's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D. Western Therapeutics Institute Preferred Stock Chart

D. Western Therapeutics Institute Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

D. Western Therapeutics Institute Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4576
47GF Score
D. Western Therapeutics Institute Inc TSE:4576
Preferred Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

D. Western Therapeutics Institute Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.

Frequently Asked Questions Learn more about Preferred Stock →
What does a Preferred Stock of 円0.00 Mil mean?
D. Western Therapeutics Institute (TSE:4576) has a Preferred Stock of 円0.00 Mil as of Dec. 2025. Preferred Stock represents the par value of a company's preferred shares. View historical data on D. Western Therapeutics Institute and its competitors.
Is D. Western Therapeutics Institute's Preferred Stock too high?
D. Western Therapeutics Institute's current Preferred Stock is 円0.00 Mil. Overall, D. Western Therapeutics Institute has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's Preferred Stock compare to VRTX and REGN?
D. Western Therapeutics Institute's Preferred Stock of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Stock for a Biotechnology company?
A good Preferred Stock depends on the Biotechnology industry context. However, Preferred Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Stock mean?
A high Preferred Stock can signal that a stock is expensive relative to its fundamentals. Preferred Stock represents the par value of a company's preferred shares. View historical data on D. Western Therapeutics Institute and its competitors. D. Western Therapeutics Institute's current Preferred Stock is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (TSE:4576) is currently considered Fairly Valued. The stock's GF Value™ is 円68.18, compared to a current price of 円75.00 — trading 10% above its estimated fair value. The current Preferred Stock is 円0.00 Mil. D. Western Therapeutics Institute's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Stock calculated?
Preferred Stock is calculated from a company's financial statements. For D. Western Therapeutics Institute (TSE:4576), the current Preferred Stock is 円0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is D. Western Therapeutics Institute (TSE:4576) Overvalued in 2026?

Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued. The current stock price of 円75.00 is trading 10% above its estimated GF Value™ of 円68.18. GuruFocus considers D. Western Therapeutics Institute to be Fairly Valued.

Key valuation signals for TSE:4576:

  • Preferred Stock: 円0.00 Mil
  • GF Value™: 円68.18 vs. price of 円75.00 (10% above fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the TSE:4576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


D. Western Therapeutics Institute Business Description

Other Exchanges 6DW:Germany
Address 7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
47GF Score

Get the complete analysis for TSE:4576

Preferred Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円75.00
Price
円68.18
GF Value